Rivastigmine hydrogen tartrate on stroke patients with vascular dementia:study of magnetic resonance spectroscopy

黄延焱,吴晓琰,朱珍,耿道颖
DOI: https://doi.org/10.3760/j.issn:1006-7876.2004.05.006
2004-01-01
Abstract:Objectives: To examine the clinical usefulness of magnetic resonance spectroscopy (MRS) on assessment of vascular dementia (VD) in patients with stroke; the relationships between metabolic changes of brain and clinical symptom improvements after giving rivastigmine in these patients. Methods: 20 stroke patients without VD, male 17, female 3, with a mean age of (71.7 ± 4.7) years old; 23 stroke patients with VD, male 20, female 3, a mean age of (72.9 ± 5.1) years old; 20 normal volunteers were studied, a mean age of (70.9 ± 4.8) years old. MRS was performed in all these patients. The patients with VD were prescribed rivastigmine hydrogen tartrate ("Exelon", Norvatis), and given MRS assessment half a year later. Results: The patients with VD had a significantly lower N-acetyl aspartate/Creatine (NAA/Cr) ratio (mean ± SD: left: 0.57 ± 0.30; right: 0.66 ± 0.29) and higher Choline/Creatine (Cho/Cr) ratio (mean ± SD: left: 1.79 ± 0.52; right: 1.97 ± 0.44) in bilateral temporal hippocampus area, compared to those without VD (mean ± SD; NAA/Cr: left, 0.91 ± 0.31; right, 0.87 ± 0.27, P< 0.001; Cho/Cr: left, 1.28 ± 0.27; right, 1.28 ± 0.20, P < 0.001) and normal subjects (mean ± SD: NAA/Cr: left, 1.11 ± 0.27; right, 1.16 ± 0.31, P< 0.001; Cho/Cr: left, 1.21 ± 0.27; right, 1.23 ± 0.21, P < 0.001). Relative-regression analysis found that there was a positive relationship between MMSE scores and NAA/Cr ratios (left: r = 0. 48, P = 0.024; right: r = 0.6, P = 0. 003) and negative Cho/Cr ratios (right; r = -0.53, P = 0.012), respectively, but no relationship between MMSE scores and Cho/Cr ratios in the left hippocampus area in patients with VD. After taking rivastigmine, NAA/ Cr ratios increased and Cho/Cr ratios decreased. Conclusions: The data suggest that the lower NAA/Cr ratios and higher Cho/Cr ratios in hippocampus area might be helpful in distinguish VD and no-VD in patients with stroke. Rivastigmine should also be helpful in improving metabolic changes associated with VD.
What problem does this paper attempt to address?